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Background: To compare the diagnostic yield of endobronchial 
ultrasound (EBUS) and/or endoesophageal ultrasound (EUS) with 
transcervical extended mediastinal lymphadenectomy (TEMLA) for 
primary staging and repeated staging (restaging) of non–small-cell 
lung cancer (NSCLC).
Methods: In this retrospective study, all consecutive patients under-
going primary staging and restaging after neodjuvant chemo- or 
chemo-radiotherapy for NSCLC with EBUS, EUS, or EBUS com-
bined with EUS (CUS) with fine needle aspiration biopsy and cyto-
logical examination and subsequent TEMLA from January 1, 2007 
to December 31 2010, were included.
Results: Primary staging was performed in 623 patients: EBUS 
in 351, EUS in 72, and CUS in 200 patients. TEMLA was per-
formed for primary staging in 276 patients. There was no mortality 
and morbidity after EBUS or EUS. One patient died after TEMLA 
and morbidity rate after TEMLA was 7.2%. There was a signifi-
cant difference between EBUS or EUS and TEMLA for sensitivity 
(87.8% and 96.2%; p < 0.01) and negative predictive value (82.5% 
and 99.6%; p < 0.01) in favor of TEMLA. In the restaging group, 
endoscopic staging was performed in 88 patients and TEMLA in 
78 patients. There was a significant difference between EBUS or 
EUS and TEMLA for sensitivity (64.3% and 100%; p < 0.01) and 
negative predictive value (82.1% and 100%; p < 0.01) in favor of 
TEMLA.
Conclusions: The results of this largest reported series compar-
ing the endoscopic and surgical primary staging and restaging of 
NSCLC showed a significantly higher diagnostic yield of TEMLA 
when compared with that of EBUS or EUS.
Key Words: Lung cancer, Staging, Endobronchial ultrasound, 
Esophageal ultrasound, Mediastinal lymphadenectomy.
(J Thorac Oncol. 2013;8: 630–636)
Mediastinal staging of non–small-cell lung cancer (NSCLC) includes imaging studies, with computed tomography 
(CT), positron emission tomography (PET), combined PET/CT, 
endoscopic studies, and invasive techniques, such as cervical 
mediastinoscopy, anterior mediastinotomy, and videothoracos-
copy.1 According to the current guidelines of European Society 
of Thoracic Surgeons cervical mediastinoscopy is regarded as 
the standard procedure for staging of mediastinal lymph nodes.1 
In recent years, however, there has been a progressive increase in 
the use of two endoscopic techniques: endobronchial ultrasound 
(EBUS)–transbronchial needle aspiration and endoesophageal 
ultrasound–fine needle aspiration (EUS-FNA). Some authors 
have questioned the role of mediastinoscopy as the standard 
procedure of the staging of mediastinal lymph nodes and raised 
the advantages of preoperative staging with EBUS and EUS, 
especially for avoidance of unnecessary surgical exploration.2–5 
In 2004, we introduced transcervical extended mediastinal 
lymphadenectomy (TEMLA), the technique of very high diag-
nostic yield in discovering mediastinal metastatic nodes.6 The 
aim of this study is to compare the diagnostic yield of EBUS 
and/or EUS with that of invasive staging of NSCLC performed 
with TEMLA at our hospital.
PATIENTS AND METHODS
All consecutive patients considered candidates for 
surgical treatment of NSCLC, who had undergone either 
primary staging or repeated staging (restaging) after 
neodjuvant chemo- or chemo-radiotherapy with EBUS, EUS, 
or combined EBUS with EUS (CUS) with FNA and cytological 
study of the aspirated specimen at our institution from January 
1, 2007 to December 31, 2010, were included. All patients 
underwent chest CT, and PET/CT was done selectively on a 
limited number of patients. Patients who underwent TEMLA 
without the previous endoscopic ultrasound were excluded 
from the study. The mediastinal nodal stations were described 
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according to the recent International Association for the Study 
of Lung Cancer (IASLC) map.7
Primary Staging
Primary staging was always started with CT (and PET/
CT on selective patients). The patients with M1 disease discov-
ered on CT or PET/CT were excluded from further staging. The 
mediastinal nodes that were positive on CT or PET/CT were 
always verified by the next steps of staging. CT or PET/CT was 
followed by EBUS, EUS, or CUS. The choice of the particular 
endoscopic procedure was decided by the endoscopist, based 
on the localization of the suspected nodes. Generally, EBUS 
was preferred for examination of the right paratracheal nodes 
(stations 2r and 4r). EUS was preferred for examination of 
the lower mediastinal nodes (stations 8 and 9) and for part of 
the nodes of the aorta-pulmonary window nodes (station 5, but 
only for visualization of the nodes, without needle biopsy). For 
the left paratracheal nodes (stations 2L and 4L), retrotracheal 
nodes (3P), and for the subcarinal nodes (station 7) both EBUS 
and EUS could be used. The highest mediastinal nodes (station 
1), prevascular nodes (3A), and the para-aortic nodes (6) are 
located beyond the reach of EBUS or EUS. EBUS and EUS 
were performed under mild sedation and topical anesthesia. 
EBUS-transbronchial needle aspirationwas performed using 
the BF-UC160F-OL8 videobronchoscope (Olympus Medical 
Systems Corporation, Tokyo, Japan). The technique of EBUS 
has been described in detail elsewhere.8
EUS-FNA was performed using the GF-UCT160-OL5 
videogastroscope(Olympus Medical Systems Corporation). 
The technique of EUS has been described in detail elsewhere.9
Combined ultrasound (CUS) included EUS and EBUS 
performed sequentially during the same sedation. CUS was 
usually performed in patients in whom the nodes discovered 
by EBUS were not clearly pathological.
In case of positive results (discovery of metastatic 
mediastinal nodes), the patients were referred for neoadjuvant 
chemo- or chemo-radiotherapy, depending on the opinion of 
the oncologist. In case of negative results, the patients under-
went TEMLA. The technique of TEMLA was described in 
detail elsewhere.10 In brief, it includes a 5- to 8-cm collar inci-
sion, elevation of the sternal manubrium with a special retrac-
tor, bilateral visualization of the laryngeal recurrent and vagus 
nerves, and dissection of all mediastinal nodal stations except 
the pulmonary ligament nodes (station 9).
All patients with negative TEMLA underwent thoracot-
omy for lung resection and intraoperative systematic explo-
ration for any residual mediastinal lymph nodes, unless the 
patients were in poor general condition, or there were any 
new comorbidities or complications precluding pulmonary 
resection, or the patients withdrew the consent for operation. 
Therefore, thoracotomy with pulmonary resection and sys-
tematic nodal dissection supplementing the previous TEMLA 
was the final test for the mediastinal nodal staging. In case 
of positive results (discovery of metastatic mediastinal nodes) 
the patients were referred for neoadjuvant chemo- or chemo-
radiotherapy, depending on the opinion of the oncologist. In 
patients with partial or complete response after neoadjuvant 
therapy, restaging with the imaging studies and EBUS/EUS 
was performed. The patients who were considered operable 
and had no evidence of persistent N2/3 nodes underwent pul-
monary resection and systematic nodal dissection. The num-
ber of nodes biopsied with EBUS, EUS, and CUS, and the 
number of nodes removed on TEMLA for the primary staging 
and restaging were calculated.
The diagnostic results of EBUS/EUS were compared 
with the results of TEMLA for primary staging and for restag-
ing. Further analysis included comparison of EBUS, EUS, 
and CUS for staging and restaging.
Restaging
The patients undergoing restaging with endoscopy or 
ultrasound followed by TEMLA in case of negative results 
of endoscopies were those who underwent previous primary 
staging with EBUS, EUS, or CUS at our institution and who 
were discovered to have metastatic mediastinal nodes. These 
patients were sent for neoadjuvant treatment and came back 
to our hospital after achieving partial or complete response. 
The second subgroup comprised patients who underwent the 
primary staging elsewhere and were referred to our institution 
after completion of neoadjuvant treatment. The analysis of 
patients who underwent neoadjuvant treatment after the posi-
tive result of TEMLA has been given separately in the sec-
tion describing the primary staging group because all these 
patients were restaged without the use of TEMLA.
The number of pulmonary resections performed on 
patients undergoing TEMLA for the primary staging and 
restaging and operated on after neoadjuvant therapy after pos-
itive TEMLA were recorded for descriptive purposes.
The detailed analysis of long-term survival, both in the 
primary staging and restaging, is beyond the scope of this 
study.
Statistical analysis was performed with the StatisticaTM 
(Statsoft Inc., Tulsa, OK) software package. Probability val-
ues were generated with the χ2 test and the Student’s test or 
the Mann–Whitney test. Probability values less than 0.05 were 
considered to be statistically significant.
RESULTS
Primary Staging
Positron emission tomography/Computed  
tomography
PET/CT was performed on 78 patients. Distant metas-
tases were discovered in nine patients (11.5%). All other 
patients underwent EBUS/EUS, and if found negative, moved 
to the next step, which was TEMLA. If the TEMLA was nega-
tive, the final step was thoracotomy with systematic lymphad-
enectomy. Sensitivity of PET/CT was 54%, specificity 78%, 
positive predictive value (PPV) 37%, and negative predictive 
value (NPV) 87%.
Endoscopy with ultrasound
The endoscopic ultrasound staging was performed 
on 623 patients: EBUS in 351, EUS in 72, and CUS in 200 
patients. There was no mortality or morbidity after EBUS 
and EUS.
632 Copyright © 2013 by the International Association for the Study of Lung Cancer
Zielinski et al. Journal of Thoracic Oncology  •  Volume 8, Number 5, May 2013
The mean number of nodes biopsied in the staging group 
was 2.1 (range, 1–3) during EBUS, 2.4 (range, 1–4) during 
EUS, and 3.7 (range, 2–5) during CUS. Figure. 1 shows the 
results of staging with endoscopy followed by TEMLA and 
ending with systematic lymphadenectomy during thoracot-
omy and pulmonary resection.
Transcervical extended mediastinal  
lymphadenectomy
TEMLA preceded by negative EBUS/EUS was per-
formed on 276 patients. The mean number of nodes removed 
during TEMLA for the primary staging was 32.8 (range, 
8–77). One patient died after TEMLA (30-day in-hospital 
mortality 0.4%) from myocardial infarction. There was 7.2% 
morbidity after TEMLA. The complications of TEMLA are 
listed in Table 1.
TEMLA led to the discovery of metastatic nodes in 50 
patients, including 43 patients with N2 involvement and seven 
patients with N3 metastases. There were 31 patients with sin-
gle-level involvement (29 patients with N2 and 2 patients with 
N3) and 19 patients with multilevel metastatic involvement 
(14 with N2 and 5 with N3). These patients were excluded 
from primary resection and were sent for neoadjuvant treat-
ment. The other 226 patients were considered candidates for 
primary surgery but 30 of them were not operated on for vari-
ous reasons, which are described in Table 2.
Pulmonary resections
There were 189 pulmonary resections with system-
atic lymphadenectomy and seven exploratory thoracotomies 
(3.6%) in the primary staging group (operability 196 of 226, 
86.7%; resectability 189 of 196, 96.4%) The types of pulmo-
nary resections are listed in Table 3. Two patients died after 
TABLE 1.  Complications of TEMLA for the Primary Staging 
and Restaging of NSCLC
Complication
Primary Staging 
(276 Patients)  
No. (%)
Restaging  
(78 Patients)  
No. (%)
Pleural effusion (conservative 
treatment)
3 (1.1) 1 (1.3)
Laryngeal recurrent nerve 
palsy—overall
7 (2.5) 2 (2.6)
 Temporary left nerve palsy 5 (1.8) 2 (2.6)
 Temporary right nerve palsy 0 0
 Permanent nerve palsy 2 (0.7) 0
Pneumothorax (necessitating  
chest drainage)
2 (0.7) 1 (1.3)
Pneumothorax (conservative 
treatment without chest 
drainage)
2 (0.7) 0
respiratory insufficiency 
(ventilator)
1 (0.4) 1 (1.3)
Postoperative psychosis 1 (0.4) 0
Perforation of the duodenal ulcer 1 (0.4) 0
Cerebral ischemia 1 (0.4) 0
Subarachnoid hemorrhage 1 (0.4) 0
Cardiovascular insufficiency 1 (0.4) 0
Overall morbidity 20 (7.2) 5 (6.4)
Deatha,b 1 (0.4) 0
a Cause of death: myocardial infarction.
b The mortality rate for the whole group (primary staging plus restaging) was 0.3%.
TEMLA, transcervical extended mediastinal lymphadenectomy; NSCLC, non–
small-cell lung cancer.
TABLE 2.  Reasons for Excluding Patients from Pulmonary 
Resection after Negative TEMLA for Primary Staging
Reason No. of Patients
1. Insufficient cardio-pulmonary reserves for pulmonary 
resection.
18
2. Discovery of metastatic spread unknown before TEMLA.  5
3. Decision to use induction therapy to improve marginal 
operability.
 5
4. Withdrawal of consent for operation.  1
Total 30
TEMLA, transcervical extended mediastinal lymphadenectomy.
CT, PET / CT
EBUS and/or EUS
Positive Negative
TEMLAInduction chemotherapy /Radiotherapy
Operative
treatment
Response
Restaging
(EBUS, EUS, TEMLA)
Definitive
oncological treatment
Positive Negative
Positive Negative
Operative
treatment in
selected patients
FIGURE 1.  Primary staging of patients with NSCLC. CT, 
computed tomography; EBUS, endobronchial ultrasound; 
EUS, endoesophageal ultrasound; PET, positron emission 
tomography; TEMLA, transcervical extended mediastinal 
lymphadenectomy.
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resection (mortality 2 of 196, 1.0%). There were 181 resec-
tions without residual tumor (r0) and eight with microscopic 
residual tumor (r1).
After thoracotomy, residual N2 nodes omitted during 
previous TEMLA were found in two patients (single sta-
tion 8 node in 1 patient, single station 5 nodes in the other). 
Comparison of the diagnostic yields of EBUS, EUS, and CUS 
with that of TEMLA revealed significant differences in sensi-
tivity, specificity, NPV, and PPV, in favor of TEMLA for pri-
mary staging (Table 4).
Of the 50 patients who were referred for neoadjuvant 
therapy after the positive results of TEMLA (43 N2 and 7 N3), 
25 were not restaged subsequently because of the progres-
sion of the disease or any other reason. The other 25 patients 
were restaged after neoadjuvant treatment with chest CT and 
endoscopy or ultrasound (EBUS in 17 patients and CUS in 8 
patients). The restaging was negative in all these patients who 
finally underwent thoracotomy. There were eight pneumonec-
tomies and 17 lobectomies with systematic lymphadenectomy 
including 23 of 43 patients (53.5%) with previous N2 and 
two of seven patients (28.6%) with previous N3 found on the 
previous TEMLA. Of the 25 patients, 21 patients (84%) had 
single-level metastatic mediastinal involvement on the previ-
ous TEMLA, and four (16%) had multilevel involvement. No 
residual N2–3 nodes were found in any of these patients on 
pathological examinations of the systematic lymphadenec-
tomy specimen.
Restaging after Neoadjuvant Therapy
Endoscopy with ultrasound
There were 88 patients in the restaging group, including 
32 patients who underwent EBUS, six patients who underwent 
EUS, and 50 patients who underwent CUS. There was no 
mortality or morbidity after EBUS, EBUS, and CUS. The 
mean number of nodes biopsied in the restaging group 
was 2.1 (range, 1–3) during EBUS, 2.4 (range, 1–4) during 
EUS, and 3.7 (range, 2–5) during CUS. Figure. 2 shows the 
results of restaging with endoscopy, followed by TEMLA 
and systematic lymphadenectomy during thoracotomy and 
pulmonary resection.
Transcervical extended mediastinal  
lymphadenectomy
TEMLA was performed for restaging in 78 patients. Of 
these patients, 37 had been previously staged and found posi-
tive on the primary staging with EBUS/EUS at our hospital 
and had came back after neoadjuvant therapy. The other 41 
patients were referred from other institutions after neodjuvant 
TABLE 4.  Comparison of Diagnostic Yield of EBUS/EUS and 
TEMLA for Primary Staging of NSCLC
Diagnostic 
Parameter
Primary Staging 
EBUS/EUS  
623 Patients (%)
Primary Staging 
TEMLA  
276 Patients (%) Difference (p)
Sensitivity 87.8 96.2 < 0.01
Specificity 98.7 100 = 0.03
NPV 82.5 99.6 < 0.01
PPV 99.1 100 = 0.07
Prevalence 63.1 18.4 < 0.01
EBUS/EUS, endobronchial ultrasound/endoesophageal ultrasound; TEMLA, 
transcervical extended mediastinal lymphadenectomy; NSCLC, non–small-cell lung 
cancer; NPV, negative predictive value; PPV, positive predictive value.
TABLE 3.  Types of Pulmonary Resections in Patients with 
Negative TEMLA for Primary Staging of NSCLC
Type of Operation No. of Patients
Lobectomy/bilobectomy 132 (VATS lobectomy–7)
Sleeve lobectomy 25
Left pneumonectomy 15
right pneumonectomy 14
Wedge resection  3
Exploratory thoracotomy  7
Total 196
TEMLA, transcervical extended mediastinal lymphadenectomy; NSCLC, non–
small-cell lung cancer; VATS, videothoracoscopy.
FIGURE 2.  Restaging of NSCLC after neoadjuvant treat-
ment. NSCLC, non–small-cell lung cancer. EBUS, endobron-
chial ultrasound; EUS, endoesophageal ultrasound; CUS, 
combined ultrasound; TEMLA, transcervical extended medias-
tinal lymphadenectomy; PTS, patients.
PRIMARY STAGING
ENDOSCOPY/
ULTRASOUND
623 PTS
EBUS
351 PTS
ONCOLOGICAL
NON OPERATIVE
TREATMENT
347 PTS
TEMLA
276 PTS
Positive
50 PTS
Negative
31 PTS
Negative
162 PTS
Negative
83 PTS
Positive
41 PTS
Positive
268 PTS
1
Negative
226 PTS
CUS
200 PTS
EUS
72 PTS
Positive
38 PTS
2
NEOADJUVANT
RESTAGING
NON OPERATIVE
TREATMENT
25 PTS
THORACOTOMY
25 PTS
NON OPERATIVE
TREATMENT
30 PTS
THORACOTOMY
196 PTS
RESTAGING
37 PTS
1 - One false positive patients subseqvently underwent TEMLA
2 - Two false positive patients subseqvently underwent TEMLA
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therapy. In these 41 patients, the initial diagnosis of N2 disease 
was based on chest CT findings. There was no mortality and 
morbidity rate was 6.4%. The mean number of nodes removed 
during TEMLA in the restaging group was 27.9 (range, 
10–46). There were 14 pawo partients with N2 involvement 
and one with N3 disease. Patients with no mediastinal nodal 
involvement were regarded as candidates for surgery. Two 
patients were considered unfit for pulmonary resection after 
restaging with TEMLA.
Pulmonary resections
Finally, there were 58 pulmonary resections with sys-
tematic lymphadenectomy and three exploratory thoracoto-
mies (Table 5). On thoracotomy, no residual N2 nodes omitted 
during restaging with TEMLA were found in any patient. 
Comparison of the diagnostic yields of EBUS, EBUS, and 
CUS with that of TEMLA revealed significant differences in 
sensitivity, specificity, NPV, and PPV, in favor of TEMLA for 
restaging (Table 6).
DISCUSSION
There were several recently published reports raising 
the advantages and possible superiority of EBUS and EUS in 
comparison with mediastinoscopy.3–5,11
Our results showed something different – the invasive 
staging represented by TEMLA enabled higher diagnostic 
yield than EBUS and EUS. It was also very important that 
our series was the largest ever presented for staging of 
NSCLC. This was also a very homogenous material from a 
single institution. Our results of EBUS and EUS for staging 
of NSCLC were comparable with those presented in other 
publications. Therefore, the reason for the difference of results 
in favor of TEMLA was not because of the poor results of 
EBUS and EUS at our institution. The results of TEMLA 
were significantly better than those of EBUS and EUS, despite 
significantly lower prevalence of metastatic nodes in TEMLA 
groups, both for primary staging and restaging. This was 
because of the exclusion of patients with positive nodes on 
EBUS and EUS which were the procedures used as the second 
step of staging and restaging (after CT or PET/CT) at our 
institution. The prevalence of the metastatic mediastinal nodes 
in the TEMLA group for primary staging and restaging were 
18.4% and 19.2%, respectively, which indicated the number of 
metastatic nodes omitted during previous EBUS/EUS.
There were no futile thoracotomies for the multinodal 
or multilevel metastatic involvement omitted during primary 
staging with TEMLA. Both patients, in whom the metastatic 
nodes were erroneously omitted on the primary staging with 
TEMLA, belonged to the category of minimal metastatic 
disease with better prognosis in comparison with the rest of 
patients with NSCLC with mediastinal metastatic nodes12
There were three patients with false-positive results 
on EBUS/CUS. In these patients, TEMLA was performed 
despite discovery of N2 disease because of the suspicion that 
on FNA, the biopsy was taken accidentally from the tumor 
located close to the mediastinum and not from the nodes. The 
results of the subsequent TEMLA and thoracotomy confirmed 
that there were no true metastatic mediastinal nodes in these 
patients.
Only 37 of 347 patients (10.7%) with metastatic nodes 
found on the primary staging with EBUS/EUS and subse-
quently referred for neoadjuvant therapy returned to our hos-
pital for possible restaging and/or final pulmonary resection. 
This disappointing finding clearly showed the poor prognosis 
for patients with NSCLC and metastatic mediastinal nodes.
In the current study, the mean number of biopsied nodes 
on EBUS, EUS, and CUS were 2.1, 2.4, and 3.7, respectively 
in comparison with 32.8 and 27.9 mean number of nodes 
removed with the surrounding mediastinal fatty tissue during 
TEMLA at staging and restaging, respectively. Such a big dif-
ference in the number of examined nodes was the main reason 
for the difference in the diagnostic yields among EBUS, EUS, 
CUS, and TEMLA.
The 30-day mortality rate in this study for the whole 
group of patients undergoing TEMLA (primary staging plus 
restaging) was 0.3%, which was slightly higher in compari-
son with recent publications. The mortality rates of the larg-
est series of mediastinoscopies reported by Lemaire et al.14 
and Hammoud et al.13 were 0.05% and 0.2%, respectively. The 
morbidity of TEMLA was higher in comparison with the larg-
est series of mediastinoscopies reported recently. However, 
the life-threatening vascular complications reported in these 
studies were completely avoided in our patients.13,14 Most of 
the surgical complications of TEMLA were mild and subsided 
without any treatment; the most serious complications were 
purely medical.
It must be stressed that TEMLA is not the domain of a 
single surgeon. All thoracic surgeons and senior surgical train-
ees working at our institution perform it routinely.
TABLE 5.  Types of Pulmonary Resections in Patients after 
Negative TEMLA for Restaging of NSCLC
Type of Operation No. of Patients
Lobectomy/bilobectomy 28
Left pneumonectomy 17
right pneumonectomy 13
Exploratory thoracotomy  3
Total 61
TEMLA, transcervical extended mediastinal lymphadenectomy; NSCLC, non–
small-cell lung cancer.
TABLE 6.  Comparison of Diagnostic Yields of EBUS/EUS and 
TEMLA for Restaging of NSCLC after Neoadjuvant Treatment
Diagnostic 
Parameter
Restaging  
EBUS/EUS  
105 Patients (%)
Restaging  
TEMLA  
78 Patients (%) Difference (p)
Sensitivity 64.3 96.6 < 0.01
Specificity 100 100 = 1.00
NPV 82.1 98.5 < 0.01
PPV 100 100 = 1.00
Prevalence 40.0 19.2 < 0.01
EBUS/EUS, endobronchial ultrasound/endoesophageal ultrasound; TEMLA, 
transcervical extended mediastinal lymphadenectomy; NSCLC, non–small-cell lung 
cancer; NPV, negative predictive value; PPV, positive predictive value.
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The rate of patients with negative results of TEMLA 
undergoing final thoracotomy was 86.7% in our primary 
staging group, which was slightly lower in comparison with the 
studies including standard mediastinoscopy before resection. 
The reported rates of resection after negative mediastinoscopy 
were 91.9% (1216 of 1323) by Hammoud et al.13 and 91.3% 
(1019 of 1116) by Lemaire et al.14, respectively. The difference 
might express greater invasiveness of TEMLA in comparison 
with standard mediastinoscopy.
A subsequent thoracotomy was performed in 50% 
of patients who were referred for neoadjuvant therapy after 
discovery of metastatic nodes on the primary staging with 
TEMLA. The rate of thoracotomy was higher in patients with 
N2 versus N3 disease and in single-level versus multilevel 
metastatic involvement.
We performed pulmonary resection on several patients 
with positive N2 nodes discovered on restaging with TEMLA. 
A detailed analysis of this subgroup of patients is beyond the 
scope of this article.
We used PET/CT only in a limited number of patients 
because the access to this technology was relatively difficult 
at that time in our country. Lack of routine use of PET/CT in 
all patients is a limitation of our study, especially because it 
is currently recommended as a standard test in preoperative 
staging in NSCLC.15,16 Currently, all patients treated surgically 
for NSCLC at our institution undergo PET/CT.
Our current institutional algorithm for staging and 
restaging of NSCLC combines EBUS/EUS and TEMLA 
(Fig. 3). This algorithm is very similar to the one proposed by 
de Leyn et al.1 in the European Society of Thoracic Surgeons 
guidelines. The only most important difference is the substi-
tution of mediastinoscopy with TEMLA, which is a logical 
consequence of our results.
In our opinion, before TEMLA becomes a standard 
staging technique, maybe even the standard procedure of 
the mediastinal staging, the community of thoracic surgeons 
should adopt this technique as a normal part of the surgical 
practice and should confirm that safety and favorable results 
of TEMLA in their hands are similar to ours.
CONCLUSION
The results of the largest reported series comparing 
endoscopic and surgical primary staging and restaging of 
NSCLC showed a significantly higher diagnostic yield of 
TEMLA in comparison with EBUS/EUS. Therefore, TEMLA 
should be introduced in clinical practice as a way to increase 
the yield of ultrasound-guided endoscopic procedures and 
mediastinoscopy, with the objective of achieving a more pre-
cise preoperative nodal staging and to make more solid thera-
peutic decisions.
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